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response in this disease while leaving the remainder of the immune system intact has long been 
sought. Proinsulin is a major target of adaptive immunity in T1D. We hypothesized that an 
engineered DNA plasmid encoding proinsulin (BHT-3021) would preserve β cell function in T1D 
patients through reduction of insulin-specific T cells. We studied 80 subjects over 18 years of age 
who were diagnosed with T1D within 5 years. Subjects were randomized 2:1 to receive 
intramuscular injections of BHT-3021 or BHT-placebo, weekly for 12 weeks, and then monitored 
for safety and immune responses in a blinded fashion. Four dose levels of BHT-3021 were 
evaluated: 0.3, 1.0, 3.0, and 6.0 mg. C-peptide served as an exploratory measure of efficacy and 
safety. Islet-specific CD8+ T cell frequencies were assessed with multimers of monomeric human 
leukocyte antigen class I molecules loaded with peptides containing pancreatic or unrelated 
antigens. No serious adverse events related to BHT-3021 occurred. C-peptide levels improved 
relative to placebo at all doses, most notably at 1 mg at 15 weeks (+19.5% BHT-3021 versus 
−8.8% BHT-placebo, P < 0.026). Proinsulin-reactive CD8+ T cells, but not T cells against 
unrelated islet or foreign molecules, declined in the BHT-3021 arm (P < 0.006). Thus, we 
demonstrate that a plasmid encoding proinsulin reduces the frequency of CD8+ T cells reactive to 
proinsulin while preserving C-peptide over the course of dosing.
INTRODUCTION
One of the hallmarks of type 1 diabetes (T1D) is an inflammatory response that ultimately 
destroys the β cells of the pancreas, a process termed insulitis. CD8+ T cells directed to 
various islet antigens including preproinsulin (PPI), glutamic acid decarboxylase (GAD), 
tyrosine phosphatase–like insulinoma antigen (IA2, also called ICA512), zinc transporter 
ZnT8, and islet-specific glucose-6-phosphatase catalytic subunit–related protein (IGRP) 
have been detected in the blood and in the pancreatic islets of individuals with T1D (1–3). 
Attempts have been made to use antigen-specific therapy to delay T1D, including 
parenterally and nasally administered insulin (4–6). However, a trial of oral insulin failed to 
delay T1D, although there was evidence of delay in a subset of patients with high levels of 
insulin autoantibodies (6, 7). Other clinical trials targeting GAD with alum were 
unsuccessful in phase 3 in reducing loss of C-peptide—a marker of β cell function—
possibly due to the use of an adjuvant that failed to show efficacy in murine models of T1D 
(8). In contrast, a recent phase 3 trial of a heat shock peptide (DiaPep277) reported 
successful outcomes for preservation of C-peptide, insulin usage, and HgbA1c (9). These 
trials involving injection of self-molecules have demonstrated safety, with no serious 
adverse events reported to date.
One approach that was successful in preclinical experiments in mouse models of T1D was 
using an engineered DNA vaccine encoding the whole proinsulin molecule, including C-
peptide and insulin A and B chains, termed BHT-3021 (10–12). Tolerization to proinsulin 
prevented and reversed active insulitis in hyperglycemic nonobese diabetic mice, a widely 
studied mouse model of T1D (12). BHT-3021 is designed to decrease the antigen-specific 
autoimmune response against proinsulin in T1D. The plasmid was engineered with reduced 
numbers of proinflammatory hexanucleotide motifs, termed CpG motifs. CpG 
hexanucleotide sequences activate innate immune responses by binding to Toll-like receptor 
9 and other DNA sensors (13). All non-essential CpG sequences were replaced with GpG 
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motifs, which compete with CpG motifs. This antigen-specific plasmid vaccine approach 
has the theoretical advantage of decreasing the autoimmune response while leaving intact 
other important, desirable, physiologic roles of the immune system, such as immune 
regulatory responses against pro-insulin, immune surveillance against tumors, and immune 
responses against infectious agents.
Adaptive immune responses to islet-associated antigens have been identified in T1D. 
Pancreatic specimens obtained from T1D patients reveal a lymphocytic infiltrate in the 
pancreatic islets, composed predominantly of CD8+ T cells, with up-regulated human 
leukocyte antigen (HLA) class I molecules (1, 14). These findings suggest a key 
pathophysiologic role for cytotoxic T lymphocytes (CTL) in T1D. CD4+ T cells are also 
likely involved in the pathogenesis of T1D, further supported by the strong association of 
susceptibility in T1D with certain HLA class II haplotypes (14). Finally, autoantibodies to 
pancreatic islet antigens have been found in the overwhelming majority of T1D patients and 
those at genetic risk for developing the disease. Antibodies to either GAD, IA2, or insulin 
are present in 95% of prediabetic or new-onset T1D patients; 80% of patients are positive 
for two or more of these antibodies, and 25% are positive for all three antibodies. Multiple 
T1D-associated autoantibodies are present rarely in serum of healthy control subjects (3).
Insulin is a primary β cell–specific autoantigen, and insulin auto-antibodies are usually the 
first to appear in young children with T1D (3, 15). Furthermore, half of the T cells isolated 
from pancreatic draining lymph nodes of patients with T1D recognize an epitope of the 
insulin A chain, whereas T cells from healthy subjects that recognize this epitope have not 
been observed (16). Finally, it has been demonstrated that insulin-reactive T cells from T1D 
patients exhibit an activated inflammatory T helper 1 (TH1) cell phenotype, whereas insulin-
reactive T cells from healthy controls exhibit a protective T regulatory phenotype (17).
Thus, there is a substantial rationale for efforts to reduce the auto-immune response against 
insulin in individuals with T1D while leaving regulatory responses intact or even enhancing 
them. The safety of this approach was explored in this clinical trial, with C-peptide as 
primary clinical endpoint. Antigen-specific modulation was measured using a variety of 
assays as secondary endpoints. We demonstrate that BHT-3021 is safe and effective at 
preserving C-peptide during the period of administration and modulates insulin-specific T 
lymphocytes, but not T cells specific for other antigens.
RESULTS
Baseline characteristics of the intent-to-treat population
Table 1 shows that the baseline characteristics of the intent-to-treat (ITT) population are not 
significantly different from those randomized to control.
Prespecified efficacy endpoints
C-peptide. C-peptide secretion is considered an important surrogate marker for assessment 
of pancreatic secretion of insulin (18–20). Area under the curve of C-peptide response 
(referred to herein as “C-peptide”) to mixed-meal tolerance test (MMTT) is a validated 
method of assessing endogenous insulin secretion, and subjects with T1D have C-peptide 
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responses to an MMTT at a time when intravenous glucose and glucagon responses were 
absent (19, 20).
BHT-3021 (Fig. 1) was dosed via the intramuscular route for 12 weeks to individuals with 
T1D who had residual C-peptide at the time of screening (C-peptide >33 pM) (Fig. 2). 
Placebo received an equivalent dose of saline. At 15 weeks for 1.0-mg BHT-3021 dose 
versus BHT-placebo, the percent change from baseline in mean C-peptide was +19.5% 
(−1.95% lower confidence level, 41.0% upper confidence level) versus −8.8% for placebo 
(−25.34% lower confidence level, +7.66 upper confidence level; P < 0.026) (Fig. 3 and fig. 
S1A). Subjects in the 1.0- and 3.0-mg arms had C-peptide levels that were above the 
screening values at week 15. Figure S1B shows percent change from baseline for C-peptide 
in scatter plots of all doses and placebo at 15 weeks. In contrast, the placebo group, which 
started out higher, demonstrated a very steep decrease in C-peptide over the same 6-month 
period. One potential caveat was a longer mean time from diagnosis for the 1-mg group 
(59.7 months) compared to placebo (41.1 months), although this difference was not 
statistically significant (Table 1). These data suggest that BHT-3021 may preserve β cell 
mass and/or function during the dosing period of 12 weeks and for up to 3 more months (6-
month time point) after cessation of dosing. This effect is ultimately lost after 
discontinuation of therapy. Table S1 shows that treatment with BHT-3021 is not associated 
with a large reduction in C-peptide.
Mean HbA1c, insulin requirements, and blood glucose levels—HbA1c allows a 
measure of the changes in glucose homeostasis, over a long segment, because it reflects the 
glycosylation of hemoglobin, and thus reflects the status of plasma glucose, with the 
predominant contribution from plasma glucose over the past month. Generally, levels of 
HbA1c above 53 mmol/mol (7.0%) are considered diabetic, with standards varying 
depending on the organization who is deciding the guideline. Figure S2A displays the mean 
HbA1c by treatment group for the MMTT population. Differences in baseline HbA1c among 
the groups were noted, reflecting varying levels of glycemic control at entry. The mean 
HbA1c was relatively stable at entry and at 15 weeks, and then increased after cessation of 
dosing at month 6 in all groups, although the differences were not statistically significant. 
Notably, there was a decrease in monitoring with fewer study visits beyond week 15. Figure 
S2B displays the mean total insulin usage by treatment group. Total insulin usage was stable 
for the treatment groups for the initial 6 to 9 months of the study and then increased 
subsequently. Mean insulin usage for the 1-mg dose fell during the period of dosing. The 
overall increase in insulin usage was concurrent with higher HbA1c. In particular, over the 
duration of study drug dosing, insulin usage was stable when compared to baseline in each 
of the treatment groups, although the differences were not statistically significant from 
placebo.
Immunological studies
Enumeration of antigen-specific CD8+ T cells during therapy—A prespecified 
immunological study was designed to quantify the changes in islet-specific CD8+ T cells 
before and after treatment with BHT-3021. All patients were typed for HLA. Sixty-four 
patients had HLA class I types for which multimers were available. Twenty-one of the 64 
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patients had too few cells at baseline to allow comparison over time. Two patient samples 
were not collected. Therefore, a total of 41 of the 80 patients were evaluated at baseline and 
at least one time point after treatment. We used the combinatorial quantum dot (Qdot) 
technique (21) to simultaneously detect CD8+ T cells specific for nine different β cell–
derived antigens, and a cadre of viral epitopes, to measure responses to non-islet antigens 
(21).
We analyzed delta (stimulated) C-peptide in relation to changes in CD8 islet autoreactivity 
from baseline in patients treated with active drug compared to placebo, for each of the 
epitopes tested, and for HLA-A2, HLA-A3, and HLA-B7. We then distinguished epitopes 
present in the BHT DNA vaccine (that is, proinsulin, but not the leader peptide in PPI) from 
other islet autoantigens [GAD, IA2, PPI leader sequence, islet amyloid polypeptide (IAPP), 
and IGRP]. Finally, we accounted for one insulin epitope (insulin B10-18), which is also 
present in injected insulin, which was used for insulin replacement therapy in all patients in 
the study (22). Because it is known that immune responses to injected insulin may develop 
after initiation of insulin therapy, insulin replacement may act as confounder regarding 
changes induced by BHT-3021. Therefore, CD8+ T cell responses to this epitope were 
separated from the two other epitopes present in BHT-3021. Finally, we distinguished no 
change in T cell response (δ = 0) in cases where there was no response detectable at any 
time reliably, from those where the frequencies were the same at t = 0 and 15 weeks.
When the change in the frequency of CD8 lymphocytes to pro-insulin was compared with 
the percent change in the mean C-peptide, there was a negative correlation for proinsulin, 
but not for insulin or other β cell antigens including preproinsulin, IA2, IGRP, GAD65, or 
prepro-IAPP (ppIAPP) (Fig. 4; P = 0.006 for HLA-A3 proinsulin, treated versus placebo, 
using linear regression analysis, n = 12 and 8, respectively; P > 0.05 for all other epitopes). 
These results indicate that BHT-3021 induced antigen-specific reductions in CD8 cells 
reactive to proinsulin, but not to other antigens, and that the magnitude of the reduction was 
inversely correlated with the improvement in C-peptide.
Analysis of the frequencies of virus-specific CD8+ T cells over time showed no differences 
between treated subjects and placebo. CTL frequencies against vaccine epitopes 
significantly increased in placebo over time compared to treated patients (P = 0.003 using 
one-tailed Mann-Whitney test at week 15; n = 16 for placebo and n = 30 for treated; see fig. 
S3A). For proinsulin HLA-A3–specific CD8+ T cells, differences in placebo versus treated 
were most pronounced at week 15, with differences waning after cessation of therapy (n = 8 
for placebo and n = 16 for treated; P = 0.0142 using Mann-Whitney test at week 15; fig. 
S3B).
Treatment arms were evenly distributed for the criterion of baseline CD8 islet autoreactivity, 
ruling out the possibility that the changes in T cell response to BHT-3021 at 15 weeks were 
due to selective imbalance seen at time 0 (fig. S4).
Enzyme-linked immunospot analysis of cytokine production in CD4 T cells 
specific for insulin B9-23 and other islet cell antigens—We chose to measure 
interferon-γ (IFN-γ) and interleukin-10 (IL-10), because IFN-γ is the major TH1 cytokine 
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and IL-10 is a key cytokine produced by regulatory T cells. There was no consistent change 
in IL-10 immune responses to any islet epitopes including those contained in BHT-3021 as 
well as those unrelated to BHT-3021 (fig. S5A), and no change in IFN-γ responses to the 
immunodominant insulin epitope (fig. S5B), at 15 weeks. There were insufficient data 
available for correlation of enzyme-linked immunospot (ELISpot) analysis and CD8 
multimer analysis for the same patient at matching time points.
Autoantibodies to pancreatic antigens—Autoantibodies to pancreatic antigens were 
measured at baseline and week 15 (3 weeks after the final BHT-3021 administration) in all 
subjects for which samples were available. In general, there were few changes in antibody 
status at week 15 such that individuals who were positive at baseline for a specific antibody 
maintained positivity at week 15, and, conversely, if they were negative at baseline, they 
remained negative at week 15 (table S2). A few exceptions existed, specifically a single 
placebo subject who converted from negative to positive for GAD65, and four subjects (two 
active and two placebo) converted from negative to positive for insulin antibodies (IAs). No 
subjects converted from negative to positive for IA2.
Because the plasmid DNA BHT-3021 encodes the proinsulin protein, changes in the 
immune response to insulin were of particular interest. To determine whether the change in 
IA status in these four subjects correlated with any clinical outcomes, the changes in C-
peptide at week 5, week 15, and month 6 for the subjects converting from negative to 
positive for IA confirmed that there were no consistent C-peptide changes that correlated 
with the induction of IAs. The subject with the largest induction of IA had the best 
preservation of C-peptide over time. We conclude that the induction of IA did not correlate 
with an undesirable precipitous decline in C-peptide in these subjects.
Safety
Treatment-emergent adverse events—The independent Data and Safety Monitoring 
Board (DSMB) determined that there were no treatment-related adverse events that appeared 
to be related to the study drug. Detailed description of all treatment-emergent adverse events 
(TEAEs) is presented in table S3. Summary statistics consisted of numbers and percentages 
of subjects for categorical measures and means, medians, SDs, and minimum and maximum 
values for continuous measures as calculated with version 9.1.3 of the SAS statistical 
software package for the calculation of all summaries, listings, graphs, and statistical 
analyses of adverse events.
TEAEs were reported for 12 (85.7%) of 14 subjects treated with 0.3 mg of BHT-3021, 18 
(100%) of 18 subjects treated with 1.0 mg, 11 (78.6%) of 14 subjects treated with 3.0 mg, 7 
(87.5%) of 8 subjects treated with 6.0 mg, and 25 (96.2%) of 26 subjects treated with BHT-
placebo. Grade 3 or higher TEAEs were reported for 4 (28.6%) of 14 subjects treated with 
1.0 mg of BHT-3021, 2 (28.6%) of 14 subjects treated with 3.0 mg, 3 (37.5%) of 8 subjects 
treated with 6.0 mg, and 4 (15.4%) of 26 subjects treated with BHT-placebo. The various 
types of TEAEs, none related to the study drug, are summarized in table S3. TEAEs 
considered to be possibly related to study drug were reported for 5 (35.7%) of 14 subjects 
treated with 0.3 mg of BHT-3021, 6 (33.3%) of 18 subjects treated with 1.0 mg, 6 (42.9%) 
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of 14 subjects treated with 3.0 mg, 4 (50.0%) of 8 subjects treated with 6.0 mg, and 6 
(23.1%) of 26 subjects treated with BHT-placebo. Most of these events were noted by the 
investigator to be grade 1; a few were grade 2 events. Serious TEAEs were reported for 1 
(7.1%) of 14 subjects treated with 0.3 mg of BHT-3021, 1 (5.6%) of 18 subjects treated with 
1.0 mg, and 4 (15.4%) of 26 subjects treated with BHT-placebo; none of these events was 
considered to be related to study drug.
Discontinuations—Two subjects treated with 3.0 mg of BHT-3021 were discontinued 
from study drug treatment because of TEAEs that investigators could not be certain were 
unrelated to study drug. One subject reported a grade 2 headache, and one subject developed 
grade 1 vaginal candidiasis. Upon completion of the trial and review of data on all patients, 
there was no statistical association of these particular adverse events, or any others, to study 
drug. There were no deaths in the study. We conclude that BHT-3021 met its primary 
endpoint for safety, with no substantial toxicities noted.
DISCUSSION
There is no approved immunotherapy for the treatment of T1D. The mainstay of treatment is 
insulin replacement, a lifesaving breakthrough that was discovered more than 90 years ago. 
A therapeutic agent that targets the primary pathogenesis of the disease has long been 
sought.
A major autoimmune response in T1D is directed to insulin (1–3, 5, 6). Here, we have 
attempted to modulate, in an antigen-specific manner, the adaptive immune response to 
proinsulin with an engineered DNA vaccine encoding proinsulin. The vaccine is engineered 
to reduce the immunogenicity of the encoded proinsulin by substituting CpG hexameric 
motifs, which stimulate the innate immune response, with GpG hexameric nucleotide 
sequences, known to modulate innate immunity (13). Here, we show that this approach 
modulated C-peptide, with an actual rise in this marker of β cell function during the dosing 
period at two doses. We also demonstrate that as the C-peptide increases, there is a deletion 
of CD8+ T cells reactive to proinsulin, but there is no effect on other antigen-specific T cell 
responses. This is a firm indication that antigen-specific modulation has occurred.
There was no increase in adverse events or in serious adverse events associated with 
BHT-3021 (table S3). This is a particularly important outcome because T1D is more 
commonly observed in children and young adults in whom BHT-3021 will ultimately need 
to be tested.
We assessed C-peptide to ascertain whether this vaccine might impact the levels of C-
peptide. We observed significant improvement in C-peptide during the dosing period. The 1-
mg dose was most effective compared to placebo (P < 0.026) (Fig. 3). Treatment with 1.0 
and 3.0 mg of BHT-3021 led to C-peptide levels that were above the screening values at 
week 15. Thus, these data provide evidence of preservation of C-peptide during the dosing 
period, an effect that was lost when subjects were no longer exposed to the antigen-encoding 
vaccine. This result is surprising and unexpected because the trial was not powered to 
measure efficacy outcomes and because the trial was performed in adults with disease 
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duration up to 5 years and proportionately lower β cell mass and perhaps more end-stage 
immune responses than those observed in recent-onset diabetic subjects.
HgbA1c was well controlled during dosing of the DNA plasmid compared to placebo (fig. 
S2A). The mean HbA1c was relatively stable initially through 15 weeks of treatment with 
BHT-3021 and then increased at month 6 in all groups. Insulin usage appeared relatively 
stable overall when compared to baseline in each of the treatment groups (fig. S2B). The 
data from week 104 are not statistically significant (n = 3). Neither the HbA1c nor the insulin 
usage data were significantly different from control at any dose.
CD8+ T cells are critical in the pathogenesis of T1D (1–3, 5, 6). CD8+ T cells specific for 
proinsulin, other islet cell antigens, and viral antigens were assessed with HLA class I 
multimers, a technology that allows for enumeration of the frequency of antigen-specific T 
cells with flow cytometry (21, 23). We demonstrate antigen-specific reduction in CD8 cells 
reactive to proinsulin, but not to other antigens, and that the magnitude of the reduction was 
inversely correlated with the improvement in C-peptide (Fig. 4).
CD8+ T cells specific for proinsulin have been detected in the islets of patients with T1D 
using the same HLA monomers used in our studies (1). Reduction in the frequency of such 
CD8+ T cells in this study correlated with increases in C-peptide during the period of dosing 
(Fig. 4). We speculate that proinsulin-specific CD8+ T cells are either deleted by apoptosis 
because they receive signals through their cognate T cell receptors in the absence of 
costimulatory signals provided by antigen-presenting cells or actively suppressed by 
regulatory T cells and sequestered from the pancreatic islets and from the peripheral 
circulation where we attempted to detect them.
The particular HLA types and epitopes used in the analysis with multimers are relevant to 
the pathophysiology of T1D. A recent study using tetramers, rather than the Qdot multimers 
used in the current paper, but with the same HLA molecules and islet epitopes as the ones 
used in the current experiments for BHT-3021, detected similar CD8+ T cells in peripheral 
blood, which are also seen in the inflamed pancreas of the same patient with T1D (24). 
Thus, these peripheral CD8+ T cells found in the circulation are known to locate in the 
inflamed islets (24). Another recent investigation revealed that CD8+ T cells cloned from 
peripheral blood and reactive against one of the epitopes in the multimer study used in this 
paper were pathogenic (25). These CD8 clones caused insulitis and β cell destruction when 
injected into humanized (HLA-A2 transgenic) mice, demonstrating diabetogenicity of these 
particular circulating islet autoreactive human CD8+ T cells detected in our assay in this 
clinical trial (25). These T cells under investigation in this clinical trial may thus have real 
pathogenic relevance to T1D (24, 25).
Limitations of this study include the fixed dosing regimen and limited dosing period. It is 
possible that other dosing regimens will provide more robust benefit in the initial dosing 
period and/or in the maintenance of tolerance in extended dosing. In addition, because of the 
limited dosing period, it is unclear whether long-term benefit in T1D can be achieved. 
Follow-on studies are needed to assess the activity of alternative dosing regimens in both the 
initiation and maintenance of antigen-specific tolerance as well as to assess the durability of 
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the effect of continued dosing. The Qdot assay used in Fig. 4 could be used to optimize dose 
and frequency as we strive to attain depletion of CD8+ T cells to proinsulin while 
maintaining stability of other antigen-specific T cells.
Together, the preservation of C-peptide during the period of dosing of BHT-3021, along 
with the immunological studies with major histocompatibility complex class I multimers, 
indicates that BHT-3021 induces antigen-specific modulation of the immune response to 
proinsulin, but not to other antigens. A long sought-after goal of therapy in autoimmune 
disease aims to reduce or abolish the unwanted autoimmune responses that contribute to 
pathology. There is strong evidence that immunity to insulin, a primary β cell–specific 
antigen, is one of the fundamental aspects underlying the pathophysiology of T1D. The 
results of this 12-week trial with an engineered DNA plasmid encoding proinsulin indicate 
that there is antigen-specific suppression of immunity to proinsulin during the period of 
dosing. Longer trials with BHT-3021 are warranted, given the reduction in immunity to 
proinsulin and the favorable safety profile.
MATERIALS AND METHODS
Plasmid construction
BHT-3021 is a 3.3-kb bacterial plasmid expression vector containing the coding sequences 
for the hINS gene. Important functional and control features of BHT-3021 were engineered 
into the final construct, including the human CMV immediate-early gene promoter/
enhancer, a chimeric intron sequence, the bovine growth hormone gene polyadenylation 
signal, the kanamycin resistance gene, and the pUC origin of replication for propagation of 
the vector in E. coli. The backbone of BHT-3021 was modified to decrease the number of 
immunostimulatory CpG sequences. All nonessential CpG motifs were then substituted with 
immunomodulatory sequences, known as GpG sequences (13). Figure 1 shows the main 
structural features of BHT-3021. BHT-3021 was formulated in phosphate-buffered saline 
(PBS) containing 0.9 mM Ca2+ as a sterile solution for intramuscular injection at a 
concentration of 2.0 mg DNA/ml. Placebo patients received PBS.
Enrollment and recruitment
The study was performed with informed consent from all subjects and under protocols that 
were approved by the Institutional Review Boards at each institution. Before initiating the 
clinical trial, an Investigational New Drug Application was submitted to and accepted by the 
U.S. Food and Drug Administration and approval from the National Institutes of Health 
Recombinant DNA Advisory Committee was obtained. A total of 144 subjects were 
screened for the study. Eighty subjects (48 in the dose escalation cohorts and 32 subjects in 
the expansion cohort) were randomized. Inclusion criteria were as follows: (i) diagnosis of 
type 1a diabetes mellitus based on American Diabetes Association criteria; (ii) between 18 
and 40 years of age; (iii) within 5 years of diagnosis of T1D; (iv) detectable fasting C-
peptide; (v) C-peptide increase during MMTT with a minimal stimulated value of ≥0.2 
pmol/ml; (vi) presence of antibodies to at least one of the following antigens: insulin, 
GAD65, or IA2 (if IA-positive only, determination must have been completed within 2 
weeks of insulin initiation); (vii) agreement to intensive management of diabetes with an 
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HbA1c goal of <7.0%; (viii) if female, subjects must have been (a) surgically sterile and (b) 
postmenopausal or, (c) if of reproductive potential, subjects must have been willing to use 
medically acceptable birth control (for example, female hormonal contraception, barrier 
methods, or sterilization) until 3 months after completion of any treatment period; (ix) if 
male and of reproductive potential, subjects must have been willing to use medically 
acceptable birth control until 3 months after completion of any treatment period, unless the 
female partner was postmenopausal or surgically sterile; (x) serum creatinine ≤1.5 × upper 
limit of normal (ULN); (xi) aspartate aminotransferase <2 × ULN; and (xii) white blood 
cells (WBCs) ≥3 × 109/liter; platelets ≥100 × 109/liter; and hemoglobin ≥10.0 g/dl. 
Exclusion criteria were as follows: (i) unable or unwilling to comply with the requirements 
of the study protocol; (ii) body mass index >30 kg/m2; (iii) unstable blood sugar control, 
defined as one or more episodes of serious hypoglycemia (hypoglycemia that required the 
assistance of another person) within the 30 days before enrollment; (iv) previous immune 
therapy for T1D; (v) administration of an experimental agent for T1D at any time, or use of 
an experimental device for T1D within 30 days before screening, unless approved by the 
Medical Monitor; (vi) history of any organ transplant, including islet cell transplant; (vii) 
active autoimmune or immune deficiency disorder other than T1D (such as sarcoidosis and 
rheumatoid arthritis), unless approved by the Medical Monitor; (viii) 24-hour urinary 
albumin excretion >300 mg at screening; (ix) uncontrolled or untreated retinopathy at 
screening; (x) serum bilirubin > ULN, except those subjects whose abnormal values were 
attributed to any stable, benign condition (such as Gilbert's syndrome); (xi) thyroid-
stimulating hormone outside the normal range at screening, except those subjects on stable 
doses of thyroid hormone replacement therapy; (xii) known HIV positivity or evidence of 
high-risk behavior; (xiii) active hepatitis B or active hepatitis C infection; and (xiv) pregnant 
or lactating women.
Trial design
The overall study design is shown in Fig. 2. Subjects were screened for eligibility within 6 
weeks before randomization. Subjects were randomized to BHT-3021 or BHT-placebo (PBS 
vehicle) in a 2:1 ratio and entered the blinded treatment period when BHT-3021 or BHT-
placebo was administered intramuscularly weekly for 12 weeks (weeks 0 to 11). Four weeks 
after the last dose of BHT-3021 or BHT-placebo (week 15), subjects underwent a complete 
evaluation for safety, β cell function, and anti-insulin responses. Subjects were monitored 
for safety and immune response in a blinded fashion until 12 months after the first dose of 
BHT-3021 or BHT-placebo (the blinded evaluation period). Each subject's treatment 
assignment was then unblinded. Subjects who received BHT-3021 entered a 12-month long-
term follow-up period, during which they were monitored for delayed adverse events, 
pancreatic function, and immune response. Subjects who received BHT-placebo were 
eligible for crossover to receive 12 weeks of treatment with BHT-3021 in an open-label 
manner.
Eighty subjects were enrolled in the study. Four dose levels of BHT-3021 were evaluated: 
0.3, 1.0, 3.0, and 6.0 mg. An initial nine subjects were enrolled into an open-label cohort. 
After completion of the dose-finding phase of the study (dose escalation phase), additional 
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subjects were enrolled to expand one or more dose cohorts to obtain additional safety and 
efficacy data (expansion phase).
Clinical primary and secondary endpoints
The primary objective was to evaluate the safety of BHT-3021 given as weekly injections 
over 12 weeks. The secondary objectives were to evaluate the effect of BHT-3021 on 
antibody and T cell responses to diabetes-related antigens (insulin, GAD65, and IA2), to 
describe changes in pancreatic β cell function after treatment with BHT-3021, and to 
describe changes in insulin requirements and blood glucose levels after treatment with 
BHT-3021.
Primary endpoints—The safety parameters assessed in the study were adverse events and 
serious adverse events, physical examinations, vital signs, clinical laboratory testing 
(hematology, chemistry, urinalysis), ophthalmologic examination, 12-lead 
electrocardiography, 24-hour urine protein, stimulated C-peptide levels, pregnancy testing, 
and glucose measures (nighttime and self-monitored blood glucose).
Secondary endpoints—C-peptide was used as both an exploratory efficacy measure and 
a safety measure to ensure that no marked decline in pancreatic function was observed with 
treatment with BHT-3021. Markers of metabolic control included HbA1c and fasting plasma 
glucose. Total daily insulin dose was assessed at baseline and during the study. The 
pharmacodynamic parameters assessed in the study were (i) immune response to pancreatic 
antigens, as measured by antibodies to insulin, GAD65, and IA2, as well as T cell responses 
to pancreatic antigens, and (ii) blood markers of immune activation.
Antibodies to pancreatic antigens
Radioimmunoassays were performed on baseline samples to determine the initial immune 
response to insulin. Analysis at subsequent time points was used to evaluate any change in 
the response that may have resulted from BHT-3021 treatment. Analysis of reactivity to 
GAD65 and IA2 was also measured as an overall indication of autoimmune responses to 
islet antigens. Antibodies to GAD65, IA2, and insulin were measured at screening and were 
part of the entry criteria. Methods for detecting T1D-associated antibodies have been 
described previously (3, 26).
Qdot HLA-peptide multimers for measurement of frequency of antigen-specific CD8+ T 
cells
Multimeric HLA-A2–peptide complexes were prepared as previously described (21). 
Briefly, recombinant HLA-A2 and human β2-microglobulin were solubilized in urea and 
injected together with each synthetic peptide into a refolding buffer consisting of 100 mM 
tris (pH 8.0), 400 mM arginine, 2 mM EDTA, 5 mM reduced glutathione, and 0.5 mM 
oxidized glutathione. Refolded complexes were biotinylated by incubation for 2 hours at 
30°C with BirA enzyme (Avidity). The biotinylated complexes were purified by gel 
filtration on a Superdex 75 column (Amersham Pharmacia Biotech). Multimeric HLA-
peptide complexes were produced by addition of streptavidin-conjugated Qdots (21) 
(Invitrogen) to achieve a 1:20 streptavidin-Qdot/biotinylated HLA class I ratio. Qdot-585, 
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Qdot-605, Qdot-655, Qdot-705, and Qdot-800 were used. Samples from HLA-A2/A3/B7– 
positive subjects were stained with a mixture containing nine diabetes-associated epitopes, 
an HLA-A2 epitope expressed in HLA-A2, and a mixture of viral antigens (table S4).
Cell staining with Qdot-labeled multimeric complexes
Peripheral blood mononuclear cells (PBMCs) (2 × 106) were stained simultaneously with all 
Qdot-labeled multimers (0.1 μg of each specific multimer) in 60 μl of PBS supplemented 
with 0.5% bovine serum albumin (BSA) and incubated for 15 min at 37°C. Subsequently, 10 
μl of allophycocyanin-labeled anti-CD8 (stock 1:10) and 10 μl of fluorescein 
isothiocyanate–labeled anti-CD4, anti-CD14, anti-CD16, anti-CD20, and anti-CD40 
antibodies (Becton Dickinson) were added for 30 min at 4°C. After the cells were washed 
twice, they were resuspended in PBS/0.5% BSA containing 7-aminoactinomycin D 
(eBioscience) to exclude dead cells and analyzed with the LSR II (Becton Dickinson).
Data analysis and statistical methods
Patients with HLA class I type A2, A3, or B7 were stained with the corresponding 
multimers. Data were reported as the percentage of CD8+ T cells that were specific for (or 
bound to) each multimer. Changes in antigen-specific T cell percentages were calculated by 
subtracting the baseline values from each subsequent time point.
Analysis of islet-specific immune response was performed by evaluating BHT-3021–
specific responses separately from responses not specific to this agent. For example, for each 
patient, the vaccine-specific changes were calculated for each appropriate multimer [insulin 
B10-18, PPI(76–84), and PPI(79–88)]. The evaluation of islet-specific nonvaccine responses 
was calculated for the peptides PPI(15–24), PPI(4–13), GAD65, IA2, IGRP, and ppIAPP. In 
this case, a single patient could have as many as six different data points. For islet epitopes 
in the Qdot combinatorial method, specifically, the coefficient of variation was determined 
at 10.8% (HLA-A2 peptide), 34.9% (virus mix), 15.9% (insulin B10-18), 0.0% (IA2), 0.0% 
(IGRP), 6.3% (PPI), 4.5% (GAD65), and 6.9% (ppIAPP) (21).
Changes in CTL were calculated by subtracting the baseline values from values at week 15. 
Analysis was performed on all treated (all doses) and placebo patients positive for HLA-A2, 
HLA-A3, and/or HLA-B7. Statistics were performed with linear regression analysis.
Enzyme-linked immunospot
ELISpots were performed on the first 48 patients enrolled in the dose escalation phase of the 
study. ELISpots were performed at the Barbara Davis Center for Childhood Diabetes 
(Aurora, CO). ELISpot data from these 48 patients are not presented because of low signal-
to-noise ratio. The final 32 patients were included in the expansion phase, and ELISpots 
were performed on these individuals at the Contract Research Organization (CRO) Cellular 
Technology Ltd. PBMCs from patients from Australia/New Zealand were prepared at the 
CRO Cancer Trials Australia, Melbourne. PBMCs from U.S. patients were prepared at 
Cellular Technology Ltd. Frozen PBMCs were shipped in bulk to Cellular Technology Ltd. 
where the assays were performed. IL-10 and IFN-γ antigen–specific immune responses were 
evaluated. The autoimmune response to insulin and GAD65 was measured as an indication 
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of the ongoing autoimmune response to islet antigens. The immune response to a panel of 
viral peptides was used to monitor irrelevant CD8 (not T1D-associated) immune responses. 
The immune response to mosquito antigen was used to monitor antigen-specific, but not 
diabetes-related, CD4 T cell responses.
Crossover phase
Subjects who received BHT-placebo were eligible for crossover to receive 12 weeks of 
treatment with BHT-3021 in an open-label manner. The dose of BHT-3021 during the open-
label crossover period was the “best dose” based on evaluation of available safety, immune 
response, and efficacy data. The best dose was defined as that dose or doses already 
administered in the clinical trial that the DSMB found to have an acceptable safety profile, 
and which the Sponsor determined at the time of crossover to present the best balance of 
safety, biological activity (immune response), and/or efficacy. More than one dose could 
have been designated as a best dose, as long as all doses presented comparable safety and 
efficacy profiles. Crossover subjects were fully evaluated at the end of the dosing period 
(week 15), after which they entered the open-label evaluation period that lasted until 12 
months after the first dose of BHT-3021. Finally, the subjects were entered in the 12-month 
long-term follow-up period.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Structural diagram of BHT-3021
BHT-3021 is a 3.3-kb bacterial plasmid expression vector containing the coding sequences 
for human proinsulin (hINS) gene. Important functional and control features of BHT-3021 
include the human cytomegalovirus (CMV) immediate-early gene promoter/enhancer, a 
chimeric intron sequence, the bovine growth hormone gene polyadenylation signal, the 
kanamycin resistance gene, and the pUC origin of replication for propagation of the vector 
in Escherichia coli. The backbone of BHT-3021 has been modified to decrease the number 
of immunostimulatory CpG sequences and substitute immunosuppressive sequences.
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Fig. 2. A schematic of the study trial design
Eighty subjects were enrolled in the study. Four dose levels of BHT-3021 were evaluated: 
0.3, 1.0, 3.0, and 6.0 mg. After completion of the dose-finding phase of the study (dose 
escalation phase), additional subjects were enrolled to expand select dose cohorts to obtain 
additional safety and efficacy data (expansion phase). The dose escalation portion of the 
study enrolled subjects sequentially into the 1-mg and then the 3-mg cohorts (randomized 
active/placebo, 2:1); the cohorts for the 0.3- and 6-mg dose levels were then enrolled 
concurrently. After the dose escalation enrollment was complete, subjects were randomized 
(active/placebo, 2:1) into the expansion cohort to receive BHT-3021 (at doses of 0.3, 1, or 3 
mg) or BHT-placebo. IM, intramuscular.
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Fig. 3. Mean percent change in C-peptide from baseline
C-peptide was assessed as a measure of β cell function during the 12 weekly doses and 
thereafter. C-peptide measured as described in Materials and Methods (18–20). n = 14 for 
0.3-mg dose; n = 15 for 1.0-mg dose; n = 13 for 3.0-mg dose; n = 8 for 6.0-mg dose; n = 23 
for placebo. The mean percent change from baseline (BL) ± confidence interval is displayed. 
W refers to week after initiation of 12 weekly doses at time zero, whereas M refers to month 
after initiation of 12 weekly doses at time zero.
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Fig. 4. Antigen-specific CD8+ T cells were enumerated with Qdot multimer technology using 
class I HLA multimers loaded with various antigens (21–24)
Antigen and HLA haplotype are shown in each panel. CTL frequencies are defined as 
percentage of antigen-specific CD8+ T cells. Changes in CTL from baseline to week 15 are 
shown on the y axis, and percent change in C-peptide from baseline to week 15 is shown on 
the x axis. Changes in CTL were calculated by subtracting the baseline values from values at 
week 15. (A and B) Analysis was performed on all treated (0.3 mg: diamonds, 1 mg: 
triangles, 3 mg: squares, 6 mg: circles) and placebo patients positive for HLA-A2, HLA-A3, 
and/or HLA-B7 (A) and for control antigens (B). Statistics were performed with linear 
regression analysis. AUC, area under the curve.
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Table 1
Demographics and baseline characteristics (ITT population).
0.3 mg (n = 14) 1.0 mg (n = 18) 3.0 mg (n = 14) 6.0 mg (n = 8) Placebo (n = 26)
Mean age (years) 29.6 31.5 31.8 27.6 29.3
Gender
    Male 9 (64.3%) 10 (55.6%) 6 (42.9%) 7 (87.5%) 18 (69.2%)
    Female 5 (35.7%) 8 (44.4%) 8 (57.1%) 1 (12.5%) 8 (30.8%)
Race
    Caucasian 10 (71.4%) 17 (94.4%) 11 (78.6%) 8 (100%) 22 (84.6%)
    Asian 1 (7.1%) 0 1 (7.1%) 0 1 (3.8%)
    Black 0 1 (5.6%) 1 (7.1%) 0 1 (3.8%)
    Hispanic 2 (14.3%) 0 0 0 1 (3.8%)
    American Indian or Alaska Native 0 0 1 (7.1%) 0 0
    Other 1 (7.1%) 0 0 0 1 (3.8%)
Mean time from diagnosis (months) 14.0 59.7 36.9 32.2 41.1
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